Ionis (IONS) Stock Rating Reiterated After Zanvastro Approval

H.C. Wainwright has reiterated its stock rating for Ionis Pharmaceuticals (IONS) following the approval of Zanvastro. This endorsement suggests confidence in the company's direction and potential market performance. Approval of Zanvastro is a significant event for Ionis, indicating progress in their drug development pipeline. This news may positively influence investor sentiment and trading activity for Ionis shares.